Evidence map›Paper›PMID 25888819›Full record

ArticleArthritis research & therapy2015

Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.

Mohammad S Khorasani, Sindi Diko, Allison W Hsia, Matthew J Anderson, Damian C Genetos, Dominik R Haudenschild, Blaine A Christiansen

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04303026 (A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04303026 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis

TypeinterventionalSponsorVestre Viken Hospital TrustRan2020 to 2024Enrolled70ConditionsOsteoarthritis, HipArmsZoledronic Acid, Saline 0.9%
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mohammad S KhorasaniDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. mokhoras@yahoo.com.
Sindi DikoDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. sdiko26@gmail.com.
Allison W HsiaDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. alwhsia@ucdavis.edu.
Matthew J AndersonDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. mjanderson@ucdavis.edu.
Damian C GenetosDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. dgenetos@ucdavis.edu.
Dominik R HaudenschildDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. drhaudenschild@ucdavis.edu.
Blaine A ChristiansenDepartment of Orthopaedic Surgery, University of California-Davis Medical Center, 4635 2nd Ave, Suite 2000, Sacramento, CA, 95817, USA. bchristiansen@ucdavis.edu.
University of California Davis Medical Center · US

Funding

Integration of TGFb-ALK5 on Wnt signaling and mechanotransduction in boneR01AR064255 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GENETOS, DAMIAN C · 2013 to 2017
$1.7M
The role of the inflammatory response in bone and cartilage changes following nonK01AR062603 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHRISTIANSEN, BLAINE A. · 2012 to 2016
$569k
Novel Early Intervention to Prevent Post-Traumatic OsteoarthritisR21AR063348 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAUDENSCHILD, DOMINIK R · 2012 to 2013
$372k
NIAMS NIH HHS AR062603NIAMS NIH HHS AR063348NIAMS NIH HHS AR064255NIAMS NIH HHS K01 AR062603NIAMS NIH HHS R01 AR064255NIAMS NIH HHS R21 AR063348
6 · The paper itself

Abstract

introductionPrevious studies in animal models of osteoarthritis suggest that alendronate (ALN) has antiresorptive and chondroprotective effects, and can reduce osteophyte formation. However, these studies used non-physiologic injury methods, and did not investigate early time points during which bone is rapidly remodeled prior to cartilage degeneration. The current study utilized a non-invasive model of knee injury in mice to investigate the effect of ALN treatment on subchondral bone changes, articular cartilage degeneration, and osteophyte formation following injury.

methodsNon-invasive knee injury via tibial compression overload or sham injury was performed on a total of 90 mice. Mice were treated with twice weekly subcutaneous injections of low-dose ALN (40 μg/kg/dose), high-dose ALN (1,000 μg/kg/dose), or vehicle, starting immediately after injury until sacrifice at 7, 14 or 56 days. Trabecular bone of the femoral epiphysis, subchondral cortical bone, and osteophyte volume were quantified using micro-computed tomography (μCT). Whole-joint histology was performed at all time points to analyze articular cartilage and joint degeneration. Blood was collected at sacrifice, and serum was analyzed for biomarkers of bone formation and resorption.

resultsμCT analysis revealed significant loss of trabecular bone from the femoral epiphysis 7 and 14 days post-injury, which was effectively prevented by high-dose ALN treatment. High-dose ALN treatment was also able to reduce subchondral bone thickening 56 days post-injury, and was able to partially preserve articular cartilage 14 days post-injury. However, ALN treatment was not able to reduce osteophyte formation at 56 days post-injury, nor was it able to prevent articular cartilage and joint degeneration at this time point. Analysis of serum biomarkers revealed an increase in bone resorption at 7 and 14 days post-injury, with no change in bone formation at any time points.

conclusionsHigh-dose ALN treatment was able to prevent early trabecular bone loss and cartilage degeneration following non-invasive knee injury, but was not able to mitigate long-term joint degeneration. These data contribute to understanding the effect of bisphosphonates on the development of osteoarthritis, and may support the use of anti-resorptive drugs to prevent joint degeneration following injury, although further investigation is warranted.

Indexed as

Anterior Cruciate Ligament InjuriesAlendronateAnimalsBone Density Conservation AgentsBone ResorptionCartilage, ArticularCartilage DiseasesFemaleInjections, SubcutaneousKnee InjuriesMiceMice, Inbred C57BLOsteoarthritis, KneeAlendronateBone Density Conservation Agents

Identifiers

PMID25888819
PMCPMC4355375
OpenAlexW2129719054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.